BackIterum Therapeutics Plc Overview

Iterum Therapeutics Plc Net Income

Track Iterum Therapeutics Plc's net income ($-27M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$8.98M
47.34% YoY

As of Sep 2025

Annual Net Income (TTM)

-$26.96M
11.76% YoY

Trailing 12 months ending Sep 2025

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Iterum Therapeutics Plc (ITRM) FAQ

As of the most recent data (September 2025), ITRM shows a net income of $-27M. That compares with $-31M in the prior-year period — up 11.8% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITRM's net income is now $-27M (was $-31M) — a 11.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Iterum Therapeutics Plc is outperforming or lagging.

The Healthcare sector average net income is about $16B. Iterum Therapeutics Plc is at $-27M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how ITRM stacks up against individual peers as well.

Tracking ITRM's net income over time shows whether Iterum Therapeutics Plc is scaling, shrinking, or reshaping that part of the business. The current reading is $-27M That compares with $-31M in the prior-year period — up 11.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Iterum Therapeutics Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-27M) with ownership activity and broader fundamentals.